Wed, Apr 16, 2014, 2:25 PM EDT - U.S. Markets close in 1 hr 35 mins

Recent

% | $
Quotes you view appear here for quick access.

Avanir Pharmaceuticals, Inc. Message Board

traderalph21 399 posts  |  Last Activity: 1 hour 38 minutes ago Member since: Aug 30, 2010
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • traderalph21 traderalph21 1 hour 38 minutes ago Flag

    Another AVP-825 position:
    Senior Product Manager, AVP-825
    Aliso Viejo, CA 92656
    Full Time
    POSITION DETAILS

    Primary duties and responsibilities:

    Reporting to the Marketing Director, the Senior Product Manager will be based in Aliso Viejo, CA. Working closely with other members of the marketing team, field sales, and sales training, this individual will support the marketing of AVP-825 (22 mg sumatriptan powder in a novel breath-powered device), when approved, for the acute migraine indication with a focus on health care provider audiences including neurologists, pain specialists and primary care physicians.

  • traderalph21 traderalph21 3 hours ago Flag

    Avanir's agreement with OptiNose is for North America only.

  • traderalph21 traderalph21 3 hours ago Flag

    OptiNose moved it's headquarters to Yardley in 2000. They have offices in Norway
    (their origin) and the UK. At this time Avanir's agreement is for North America only.

  • Reply to

    Optinose: Consider this

    by rayonman11 Apr 13, 2014 4:44 PM
    traderalph21 traderalph21 14 hours ago Flag

    but ray, Teva is paying big bucks. It looks like the migraine market is like the SSRI market.
    Many unsatisfied patients.

  • Reply to

    Teva buys NuPath

    by traderalph21 14 hours ago
    traderalph21 traderalph21 14 hours ago Flag

    This is a test to see if Yahoo allows a link to its own site.
    http://news.yahoo.com/teva-buys-nupathe-expand-central-nervous-system-business-130105939--finance.html;_ylt=A0SO8zT6.E1TAF0AfApXNyoA;_ylu=X3oDMTEzcjkyY3RhBHNlYwNzcgRwb3MDMQRjb2xvA2dxMQR2dGlkA1NNRTM5OV8x

  • traderalph21 by traderalph21 14 hours ago Flag

    This is buried in another thread:
    ray, how about what Teva paid for NuPath? Teva LIKES this market.
    1/21/14 NEW YORK (TheStreet) -- Teva (TEVA_) announced Tuesday that it will acquire NuPathe (PATH_) for $144 million.
    The deal will see Teva pay $3.65 in cash for each share of NuPathe. NuPathe shareholders can also receive cash payments of up to $3.15 per share if certain net sales of NuPathe's ZECUITY migraine treatment are met over time.
    As part of the deal shareholders will receive $2.15 per share in cash after net sales of ZECUITY reach at least $100 million in any four consecutive calendar quarters. The other $1 per share will be paid when net sales of the migraine treatment reach at least $300 million in any four consecutive calendar quarters. Both payment agreements are only active until "the 60th day following the ninth anniversary of the date of the first commercial sale of ZECUITY."

  • Reply to

    Optinose: Consider this

    by rayonman11 Apr 13, 2014 4:44 PM
    traderalph21 traderalph21 15 hours ago Flag

    ray, how about what Teva paid for NuPath? Teva LIKES this market.
    1/21/14 NEW YORK (TheStreet) -- Teva (TEVA_) announced Tuesday that it will acquire NuPathe (PATH_) for $144 million.
    The deal will see Teva pay $3.65 in cash for each share of NuPathe. NuPathe shareholders can also receive cash payments of up to $3.15 per share if certain net sales of NuPathe's ZECUITY migraine treatment are met over time.
    As part of the deal shareholders will receive $2.15 per share in cash after net sales of ZECUITY reach at least $100 million in any four consecutive calendar quarters. The other $1 per share will be paid when net sales of the migraine treatment reach at least $300 million in any four consecutive calendar quarters. Both payment agreements are only active until "the 60th day following the ninth anniversary of the date of the first commercial sale of ZECUITY."

  • Reply to

    Optinose: Consider this

    by rayonman11 Apr 13, 2014 4:44 PM
    traderalph21 traderalph21 16 hours ago Flag

    ray: answer triptan pill market = $3 billion
    nasal and injectable =$500 million
    They may even go after the suppository segment!
    And there's NuPath's (just acguired by Teva) Zecuity patch.

  • traderalph21 traderalph21 21 hours ago Flag

    Thumb down?
    Too sophisticated? OK, try this. Think of your AVNR shares as PBR (Pabst Blue Ribbon)
    /watch?v=56duVYLsd4Q&list=RD56duVYLsd4Q

  • traderalph21 traderalph21 22 hours ago Flag

    I think she is:
    /watch?v=_PqY9_ZAhE8

    Sentiment: Strong Buy

  • I hope so!

    Sentiment: Strong Buy

  • traderalph21 traderalph21 22 hours ago Flag

    mike, we already did that. Today (and since 3/3/14) we are looking forward.
    Hopefully Avanir will mirror Acadia's past.

  • traderalph21 traderalph21 23 hours ago Flag

    mike, you blame Avanir for the Baker Bros performance?
    They own a lot more ACAD than AVNR.
    Since 3/3/14:
    AVNR down 20.5%
    ACAD down 37%.
    ACAD has to wait until the end of the year just for Phase III results
    (about the same time as Avanir's OptiNose PUDFA).

  • Reply to

    avnr acad pran im buying

    by wekillshorts1147 Apr 15, 2014 1:18 PM
    traderalph21 traderalph21 Apr 15, 2014 1:43 PM Flag

    Of those three, I would go with avnr who is expected to jump in the
    next two months. acad has to wait until the end of this year for phase III results
    and pran recently missed it's last trial targets.

  • Reply to

    Optinose: Consider this

    by rayonman11 Apr 13, 2014 4:44 PM
    traderalph21 traderalph21 Apr 14, 2014 10:03 PM Flag

    ray, OptiNose is going after the GIANT pill market. That is why they are comparing their
    powder with the pills. They are not measuring blood levels. It looks like they are after
    a major selling point which wont be off label. A real head to head comparison.
    A small percentage of the pill market will tower over the puny liquid nasal and injection markets.

    "The primary objective for this study is to compare the proportion of attacks in which pain reduction defined as a decrease in pain intensity of at least 1 point) is achieved at 30 minutes"

    "A Randomized, Double-Blind, Double-Dummy, Active-Controlled, Cross-Over Study A Phase III Study Evaluating the Efficacy and Safety of 20 mg SuMatriptan Powder Delivered IntrAnasally With the Bi-directional Device Compared With 100 mg Sumatriptan TabletsS in Adults With Acute Migraine With or Without Aura"

  • traderalph21 traderalph21 Apr 14, 2014 5:43 PM Flag

    But you are less than a month old!

  • Reply to

    Optinose: Consider this

    by rayonman11 Apr 13, 2014 4:44 PM
    traderalph21 traderalph21 Apr 14, 2014 5:40 PM Flag

    OptiNose is NOT only going after the PUNY nasal segment . Look at the current study I just posted.

    Sentiment: Strong Buy

  • Reply to

    Optinose: Consider this

    by rayonman11 Apr 13, 2014 4:44 PM
    traderalph21 traderalph21 Apr 14, 2014 5:30 PM Flag

    Did that on Phase II onset. Why repeat with limited budget.
    ClinicalTrials.gov Identifier:
    NCT01507610
    An Open-Label, Single-Dose, Randomized, Crossover Study to Compare the Bioavailability of the Intranasal Administration of 20 mg OPTINOSE SUMATRIPTAN With 20 mg IMITREX® (Sumatriptan) Nasal Spray, 100 mg IMITREX® (Sumatriptan) Oral Tablet and 6 mg IMITREX® (Sumatriptan) Subcutaneous Injection in Healthy Subjects

    Now going after the BIG MARKET with a Phase III (with Avanir support)
    ClinicalTrials.gov Identifier:
    NCT01667679
    A Randomized, Double-Blind, Double-Dummy, Active-Controlled, Cross-Over Study A Phase III Study Evaluating the Efficacy and Safety of 20 mg SuMatriptan Powder Delivered IntrAnasally With the Bi-directional Device Compared With 100 mg Sumatriptan TabletsS in Adults With Acute Migraine With or Without Aura

    THE RESULTS ARE DUE OUT ANY TIME. Is this why you shorts recently started a campaign against OptiNose? You guys keep ignoring how much of the injection market OptiNose will take also,
    "consider" that .0482% (ray type accuracy) is $14.6 million.

    Sentiment: Strong Buy

  • Reply to

    Update-forget what I posted earlier...

    by oldbaldheadedfart Apr 14, 2014 2:32 PM
    traderalph21 traderalph21 Apr 14, 2014 4:43 PM Flag

    mike, the race to the bottom:
    Since 3/3/14
    ACAD down 36.8%
    AVNR down 23.6%
    Who do you think will go positive first?

  • Reply to

    How much more Goofy can you get....

    by congoisking Apr 14, 2014 3:37 AM
    traderalph21 traderalph21 Apr 14, 2014 2:16 PM Flag

    bigm, did you bring up the right identity? Where's your "shyt"? "hormonal checks"? Not ray?
    From the current trial:
    Approximately one-third of patients with major depressive disorder do not achieve adequate symptom control despite a series of multiple treatment trials with currently available antidepressant medication (for example a serotonin-selective reuptake inhibitor). This group of patients - representing treatment-resistant depression (TRD) - accounts for an alarmingly high public health burden and signifies a critical area of need in pharmaceutical treatment development. While current treatments are slow to act and only partially effective, new basic and clinical research focusing on the glutamate system is yielding promising new avenues for novel drug discovery. Ketamine - a glutamate N-methyl-d-aspartate (NMDA) receptor antagonist - has now been demonstrated in several studies to bring about a rapid and robust antidepressant effect, even in patients suffering from TRD. Ketamine is limited as a treatment for TRD by the need for intravenous administration and the potential for untoward medical or psychiatric adverse effects. There is an urgent need, therefore, to identify well-tolerated, orally available compounds that target the NMDA receptor as a novel treatment approach for TRD. The current project aims to test the safety, tolerability and efficacy of Nuedexta - containing the NMDA antagonist dextromethorphan.

    Sentiment: Strong Buy

AVNR
3.36+0.07(+2.13%)2:24 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.